Cerevel Therapeutics Holdings, Inc. (CERE) financial statements (2022 and earlier)

Company profile

Business Address 222 JACOBS STREET
CAMBRIDGE, MA 02141
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments566384
Cash and cash equivalents193384
Short-term investments373 
Receivables1 
Prepaid expense75
Other current assets10
Other undisclosed current assets42
Total current assets:578391
Noncurrent Assets
Operating lease, right-of-use asset2324
Property, plant and equipment2824
Long-term investments and receivables52 
Long-term investments52 
Prepaid expense21
Restricted cash and investments44
Other undisclosed noncurrent assets11
Total noncurrent assets:11155
TOTAL ASSETS:689445
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities136
Accounts payable115
Accrued liabilities11
Other undisclosed current liabilities3023
Total current liabilities:4330
Noncurrent Liabilities
Long-term debt and lease obligation3431
Operating lease, liability3431
Liabilities, other than long-term debt00
Other liabilities00
Other undisclosed noncurrent liabilities34 
Total noncurrent liabilities:6831
Total liabilities:11061
Stockholders' equity
Stockholders' equity attributable to parent579385
Common stock00
Additional paid in capital1,196775
Accumulated other comprehensive loss(1) 
Accumulated deficit(616)(391)
Total stockholders' equity:579385
TOTAL LIABILITIES AND EQUITY:689445

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
Operating expenses(220)(149)
Operating loss:(220)(149)
Nonoperating expense
(Other Nonoperating expense)
(5)(3)
Loss from continuing operations before equity method investments, income taxes:(225)(152)
Other undisclosed income from continuing operations before income taxes00
Loss from continuing operations before income taxes:(225)(152)
Income tax benefit 0
Net loss attributable to parent:(225)(152)
Other undisclosed net income available to common stockholders, basic 4
Net loss available to common stockholders, diluted:(225)(148)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
Net loss:(225)(152)
Other comprehensive loss(1) 
Comprehensive loss, net of tax, attributable to parent:(226)(152)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: